<DOC>
	<DOCNO>NCT02262767</DOCNO>
	<brief_summary>This study test hypothesis PF-06649751 continuous co-administration trimethobenzamide hydrochloride ( TMB ) safe well tolerate . Single dose PF-06649751 test study , start low dose escalate dose project current limit drug concentration .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics PF-06649751 Co-administered With Trimethobenzamide Hydrochloride Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Trimethobenzamide</mesh_term>
	<criteria>Healthy male and/or female subject non childbearing potential age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Treatment investigational drug within 30 day ( determined local requirement ) 5 half life precede first dose study medication ( whichever longer ) . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Phase 1 , Randomized , Double Blind , Placebo-Controlled , Single-Dose Escalation , Safety , Tolerability , Pharmacokinetic , PF-06649751 , Trimethobenzamide</keyword>
</DOC>